GlassScriptPhysician profile
Adelina C Salinas
NPI 1306393632
$3,451.20
in general payments reported to CMS, 2019-2025
26 companies · $725 in 2025
The $725 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $792 · 2023: $489 · 2024: $721 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.80 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $551.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $265.92 | 2022-2025 | Freestyle Libre |
| Amgen INC. | $229.18 | 2021-2025 | Evenity, Repatha, Repatha |
| Dexcom, INC. | $181.87 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $117.74 | 2021-2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $115.59 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $105.63 | 2024-2025 | Farxiga, Airsupra |
| Eisai INC. | $97.02 | 2024 | |
| Abbvie INC. | $92.62 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $83.63 | 2022-2025 | |
| Mannkind Corporation | $78.79 | 2023-2025 | Afrezza |
| Glaxosmithkline, LLC. | $78.73 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Philips North America LLC | $72.75 | 2024-2025 | Respiratory, (O58) Sleep Respiratory Care Und |
| Medtronic, INC. | $40.57 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.44 | 2022 | |
| Paratek Pharmaceuticals, INC. | $35.27 | 2025 | Nuzyra |
| Pfizer INC. | $34.81 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.52 | 2025 | Rexulti |
| Corcept Therapeutics | $24.43 | 2024 | Korlym |
| Lundbeck LLC | $21.02 | 2025 | Rexulti |
| Nevro Corp. | $19.83 | 2024 | Senza |
| Amarin Pharma, INC. | $16.98 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.18 | 2022 | |
| Exact Sciences Corporation | $13.48 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $3.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelina Salinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.